Pharma

Following the recent news that Roche’s Phase III influenza drug Xofluza met its primary endpoint for influenza prevention, Philipp Rosenbaum, Pharma Analyst at GlobalData, a leading...

Pills on a white background

Multiple big pharma companies are developing new anti-obesity drugs, including Novo Nordisk, Sanofi, and AstraZeneca and six drugs are expected to launch by 2026, according...

pills medicine healthcare

Takeda’s possible $65B takeover of Shire could be the largest deal value in pharma this year, says GlobalData a leading data and analytics company. This...

NASH webinar- Understand the NASH Market Landscape

Affecting more than 60 million people worldwide, and with no approved therapies, nonalcoholic steatohepatitis (NASH) presents a wealth of opportunities for drug developers. Join GlobalData's...

Slow growth in pharmaceutical sales over recent years has spurred considerable interest and investment into emerging global markets: Brazil, Russia, India, China and South Korea...